Published August 13, 2026 | Version v2

PAI-1 Genotype as a Conditioning Variable for Aspirin Efficacy in Female Reproductive Cancers: Parallel Hypotheses for Breast, Ovarian, and Endometrial Cancer Derived from the Relative Permissiveness Network Framework

Description

Background: Plasminogen activator inhibitor-1 (PAI-1, SERPINE1) is a validated prognostic biomarker in breast cancer endorsed by ASCO for treatment decisions in node-negative disease. Elevated PAI-1 correlates with poor prognosis in ovarian and endometrial cancer. Aspirin and other NSAIDs show inconsistent but directionally protective associations across all three cancer types. The mechanism underlying these associations remains attributed primarily to COX-2 inhibition, without accounting for the concentration-dependent, state-switching behaviour of PAI-1 or the genetic heterogeneity in baseline PAI-1 expression conferred by the rs1799889 (4G/5G) promoter polymorphism

Files

female_cancers_rpn_hypothesis (1).pdf

Files (149.5 kB)

Name Size
md5:08815a3124155912d9e34f7b26e739c4
149.5 kB Preview Download